ES2350101T3 - Nuevos ácidos arilhexadienoicos substituidos y sus ésteres que pueden ser empleados para el tratamiento y la prevención de la diabetes, de la dislipidemia y de la aterosclerosis, composiciones farmacéuticas que los comprenden y procedimientos para la preparación de los mismos. - Google Patents

Nuevos ácidos arilhexadienoicos substituidos y sus ésteres que pueden ser empleados para el tratamiento y la prevención de la diabetes, de la dislipidemia y de la aterosclerosis, composiciones farmacéuticas que los comprenden y procedimientos para la preparación de los mismos. Download PDF

Info

Publication number
ES2350101T3
ES2350101T3 ES03798876T ES03798876T ES2350101T3 ES 2350101 T3 ES2350101 T3 ES 2350101T3 ES 03798876 T ES03798876 T ES 03798876T ES 03798876 T ES03798876 T ES 03798876T ES 2350101 T3 ES2350101 T3 ES 2350101T3
Authority
ES
Spain
Prior art keywords
image
carbon atoms
oxo
formula
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03798876T
Other languages
English (en)
Spanish (es)
Inventor
Michel Brunet
Jean-Jacques Zeiller
Yves Bonhomme
Gerard Ferrand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2350101T3 publication Critical patent/ES2350101T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES03798876T 2002-10-01 2003-08-11 Nuevos ácidos arilhexadienoicos substituidos y sus ésteres que pueden ser empleados para el tratamiento y la prevención de la diabetes, de la dislipidemia y de la aterosclerosis, composiciones farmacéuticas que los comprenden y procedimientos para la preparación de los mismos. Expired - Lifetime ES2350101T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0212135A FR2845087B1 (fr) 2002-10-01 2002-10-01 Nouveaux acides arylhexadienoiques substitues et leurs esters,utilisables dans le traitement et la prevention du diabete, des dyslipidemies,de l'atherosclerose, compositions pharmaceutiques les contenant et procedes de preparation
FR0212135 2002-10-01

Publications (1)

Publication Number Publication Date
ES2350101T3 true ES2350101T3 (es) 2011-01-18

Family

ID=31985377

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03798876T Expired - Lifetime ES2350101T3 (es) 2002-10-01 2003-08-11 Nuevos ácidos arilhexadienoicos substituidos y sus ésteres que pueden ser empleados para el tratamiento y la prevención de la diabetes, de la dislipidemia y de la aterosclerosis, composiciones farmacéuticas que los comprenden y procedimientos para la preparación de los mismos.

Country Status (21)

Country Link
US (1) US7737176B2 (fr)
EP (1) EP1546083B1 (fr)
JP (1) JP4486499B2 (fr)
KR (1) KR20050070026A (fr)
CN (1) CN1325462C (fr)
AT (1) ATE477232T1 (fr)
AU (1) AU2003255412B2 (fr)
BR (1) BR0314826A (fr)
CA (1) CA2500649C (fr)
CY (1) CY1110814T1 (fr)
DE (1) DE60333765D1 (fr)
DK (1) DK1546083T3 (fr)
ES (1) ES2350101T3 (fr)
FR (1) FR2845087B1 (fr)
MX (1) MXPA05003388A (fr)
PL (1) PL374489A1 (fr)
PT (1) PT1546083E (fr)
RU (1) RU2005113717A (fr)
SI (1) SI1546083T1 (fr)
WO (1) WO2004031116A1 (fr)
ZA (1) ZA200503416B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013177360A (ja) 2011-08-02 2013-09-09 Sumitomo Chemical Co Ltd α−ケトアルデヒド化合物の製造方法
EP2758041B1 (fr) 2011-09-20 2021-01-13 Basf Se Modulateurs sous-moléculaires du récepteur de froid et de menthol trpm8 et leur utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3615157A1 (de) * 1986-05-05 1987-11-12 Schwabe Willmar Gmbh & Co 5-arylalkyl-4-alkoxy-2(5h)-furanone, zwischenprodukte und verfahren zu ihrer herstellung sowie ihre anwendung als therapeutische wirkstoffe
RU2051673C1 (ru) * 1992-02-07 1996-01-10 Общество с ограниченной ответственностью "ЛОШТАК" Антиатеросклеротическое и антиатерогенное средство
FR2849849B1 (fr) * 2003-01-13 2006-08-04 Merck Sante Sas Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
FR2869610B1 (fr) * 2004-05-03 2006-07-28 Merck Sante Soc Par Actions Si Derives de l'acide pentenoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et leurs applications therapeutiques

Also Published As

Publication number Publication date
CA2500649C (fr) 2011-07-12
US7737176B2 (en) 2010-06-15
ATE477232T1 (de) 2010-08-15
FR2845087B1 (fr) 2004-12-24
CY1110814T1 (el) 2015-06-10
KR20050070026A (ko) 2005-07-05
ZA200503416B (en) 2006-12-27
RU2005113717A (ru) 2006-01-20
JP2006501284A (ja) 2006-01-12
MXPA05003388A (es) 2005-06-22
SI1546083T1 (sl) 2010-11-30
CA2500649A1 (fr) 2004-04-15
PT1546083E (pt) 2010-11-17
PL374489A1 (en) 2005-10-31
DE60333765D1 (de) 2010-09-23
WO2004031116A1 (fr) 2004-04-15
BR0314826A (pt) 2005-08-02
FR2845087A1 (fr) 2004-04-02
JP4486499B2 (ja) 2010-06-23
CN1688534A (zh) 2005-10-26
AU2003255412A1 (en) 2004-04-23
EP1546083B1 (fr) 2010-08-11
US20060052447A1 (en) 2006-03-09
EP1546083A1 (fr) 2005-06-29
DK1546083T3 (da) 2010-10-04
AU2003255412B2 (en) 2009-09-10
CN1325462C (zh) 2007-07-11

Similar Documents

Publication Publication Date Title
US8053463B2 (en) PPAR active compounds
ES2441874T3 (es) Compuestos para el tratamiento de trastornos metabólicos
KR100704142B1 (ko) 사람 퍼옥시좀 증식 활성화 수용체(PPAR)α의 효능제로서의 치환된 페닐프로피온산 유도체
ES2315912T3 (es) Derivados de eter sustituido por hexafluorisopropanol.
US20070244155A1 (en) Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
EA011010B1 (ru) Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина
HU215448B (hu) Eljárás kinoncsoportot tartalmazó tiazolidinszármazékok előállítására
ES2293563T3 (es) Derivados del acido hexenoico, procesos para su preparacion, composiciones farmaceuticas que los contengan y su aplicacion terapeutica.
ES2364150T3 (es) Derivados del ácido butanoico, procesos para su preparación, composiciones farmacéuticas que los comprenden y sus aplicaciones terapéuticas.
ES2292132T3 (es) Derivados del acido pentenoico, procesos para su preparacion, composiciones farmaceuticas que los contiene y sus aplicaciones terapeuticas.
US7737176B2 (en) Substituted arylhexadienoic acids and esters thereof which can be used for the treatment and prevention of diabetes, dyslipidaemia and atherosclerosis, pharmaceutical compositions comprising them and processes for the preparation of them
JP4231785B2 (ja) 酪酸誘導体
US7504519B2 (en) Derivatives of pyrazoline, procedure for obtaining them and use thereof as therapeutic agents
CN116063296A (zh) 一种作为甲状腺激素β受体激动剂的化合物及其用途
US8247448B2 (en) Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and use for the treatment of dyslipidaemia, atherosclerosis and diabetes
JP2001131173A (ja) 二環式複素環誘導体